Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial

Phase 2/3 Completed NCT04075331

Condition	COPD, Eosinophilia
Phase	Phase 2/3
Sponsor	University of Leicester
Status	Completed
Enrollment	238 participants
Interventions	Mepolizumab
Start date	Sep 7, 2020
Completion date	Jun 21, 2024
Results posted	Apr 24, 2026

Summary

This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.

Time From Randomisation to Next Hospital Readmission or Death (All Cause)

Patients were followed up for up to 48 weeks (an absolute maximum of 49 weeks as the 48 week visit had a visit window of +- 1 week). · Weeks

Placebo	25.7 Weeks
Mepolizumab	24.4 Weeks

p-value	0.811
Hazard Ratio (HR)	0.96 (95% CI 0.70–1.32)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and — University of Tennessee Graduate School of Medicine
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®T — Chiesi Farmaceutici S.p.A.
Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructiv — United Therapeutics

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский